Literature DB >> 20837342

Viral hepatitis infections in southern Taiwan: a multicenter community-based study.

Jeng-Fu Yang1, Chia-I Lin, Jee-Fu Huang, Chia-Yen Dai, Wen-Yi Lin, Chi-Kung Ho, Ming-Yen Hsieh, Li-Po Lee, Nai-Jen Ho, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Ming-Lung Yu, Wan-Long Chuang, Wen-Yu Chang.   

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are major causes of liver disease in Taiwan and have a great impact on the health of this country. This study investigated the seroprevalence of HBV and HCV in southern Taiwan. Screening programs were performed from September 1999 to August 2005 for community-based surveillance of liver disease. A total of 28,797 adults from southern Taiwan, including Kaohsiung City (n = 14,036), Kaohsiung County (n = 7,713), and Pingtung County (n = 7,048) were participated. The mean age was 50.3 ± 14.6 years (range, 20-97 years), with 41.0% were men. Hepatitis B surface antigen (HBsAg), antibody to HCV (anti-HCV), and liver function tests were performed. Among the 28,797 adults, the prevalence of HBsAg(+) was 15.1% and that for anti-HCV(+) was 8.6%. The seroprevalence of HBsAg in Kaohsiung County was 18.2%, which was higher than in Kaohsiung City (14.7%, p < 0.001) or Pingtung County (12.5%, p < 0.001). The seroprevalence of anti-HCV in Kaohsiung County was 17.2%, which was higher than in the other regions (Kaohsiung City = 5.8%, p < 0.001; Pingtung County = 4.6%, p < 0.001). The prevalence of dual HBsAg and anti-HCV was 1.1% (323 patients). Tzukuan Township in Kaohsiung County was endemic for HBsAg (19.1%, 1,026/5,375 patients), anti-HCV (22.4%, 1,203/5,375 patients), and dual HBsAg/anti-HCV (3.6%, 191/5,375 patients). Subjects with anti-HCV(+) were older and had higher alanine transaminase levels than their HBsAg(+) counterparts (p < 0.001 and p < 0.001, respectively). The current study shows the epidemiological characteristics of HBV and HCV infections among adults in southern Taiwan. Viral hepatitis infections remain widely endemic in this region.
Copyright © 2010 Elsevier. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837342     DOI: 10.1016/S1607-551X(10)70073-5

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  45 in total

1.  Survival comparison between surgical resection and percutaneous radiofrequency ablation for patients in Barcelona Clinic Liver Cancer early stage hepatocellular carcinoma.

Authors:  Kiong-Ming Wong; Ming-Lun Yeh; Shih-Chung Chuang; Liang-Yen Wang; Zu-Yau Lin; Shinn-Cherng Chen; Jung-Fa Tsai; Shen-Nien Wang; Kung-Kai Kuo; Chia-Yen Dai; Ming-Lung Yu; King-The Lee; Wan-Long Chuang
Journal:  Indian J Gastroenterol       Date:  2012-08-30

2.  Novel quasi-subgenotype D2 of hepatitis B virus identified in Taiwanese aborigines.

Authors:  Huy Tran; Ming-Lung Yu; Chia-Yen Dai; I-Ling Lin; Ming-Lun Yeh; Wan-Long Chuang; Kenji Abe
Journal:  Virus Genes       Date:  2014-05-03       Impact factor: 2.332

3.  Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C.

Authors:  Jee-Fu Huang; Chao-Kuan Huang; Ming-Lung Yu; Chia-Yen Dai; Chung-Feng Huang; Wei-Wen Hung; Ming-Lun Yeh; Meng-Hsuan Hsieh; Jeng-Fu Yang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Chern Chen; Shun-Sheng Wu; Wan-Long Chuang
Journal:  Hepatol Int       Date:  2011-08-18       Impact factor: 6.047

4.  The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study.

Authors:  Chung-Feng Huang; Jee-Fu Huang; Wu-Cheng Chen; Ming-Lun Yeh; Ching-I Huang; Jeng-Fu Yang; Wan-Long Chuang; Chia-Yen Dai; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2012-08-11       Impact factor: 6.047

5.  Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy.

Authors:  Chun-Hao Chen; Jee-Fu Huang; Chung-Feng Huang; Ming-Lun Yeh; Jeng-Fu Yang; Ming-Yen Hsieh; Nai-Jen Hou; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Wan-Long Chuang; Chia-Yen Dai; Ming-Lung Yu
Journal:  Hepatol Int       Date:  2012-07-07       Impact factor: 6.047

6.  Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).

Authors:  Chun-Jen Liu; Ming-Lung Yu; Ming-Lun Yeh; Chao-Hung Hung; Kuo-Chih Tseng; Hsueh-Chou Lai; Chi-Yi Chen; Hsing-Tao Kuo; Jing-Houng Wang; Jyh-Jou Chen; Pei-Lun Lee; Rong-Nan Chien; Chi-Chieh Yang; Gin-Ho Lo; Chi-Ming Tai; Chih-Wen Lin; Jia-Horng Kao; Chen-Hua Liu; Sheng-Lei Yan; Ming-Jong Bair; Chun-Yen Lin; Wei-Wen Su; Cheng-Hsin Chu; Chih-Jen Chen; Shui-Yi Tung; Ching-Chu Lo; Pin-Nan Cheng; Yen-Cheng Chiu; Chia-Chi Wang; Jin-Shiung Cheng; Wei-Lun Tsai; Han-Chieh Lin; Yi-Hsiang Huang; Chung-Feng Huang; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Pei-Chien Tsai; Cheng-Yuan Peng
Journal:  Hepatol Int       Date:  2021-08-07       Impact factor: 6.047

7.  Factors associated with CKD in the elderly and nonelderly population.

Authors:  Ming-Yen Lin; Yi-Wen Chiu; Chien-Hung Lee; Hui-Yen Yu; Hung-Chun Chen; Ming-Tsang Wu; Shang-Jyh Hwang
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

8.  High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.

Authors:  Chun-Yuan Lee; Pei-Hua Wu; Meng-Wei Lu; Tun-Chieh Chen; Po-Liang Lu
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

Review 9.  Host factors determining the efficacy of hepatitis C treatment.

Authors:  Wan-Long Chuang; Ming-Lung Yu
Journal:  J Gastroenterol       Date:  2012-10-27       Impact factor: 7.527

10.  Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients.

Authors:  Chung-Feng Huang; Chia-Yen Dai; Ming-Lun Yeh; Jee-Fu Huang; Ching-I Huang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Liang-Yen Wang; Suh-Hang Hank Juo; Wan-Long Chuang; Yi-Ching Lin; Ming-Lung Yu
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.